

Author: Olesen O.V.
Publisher: Adis International
ISSN: 0312-5963
Source: Clinical Pharmacokinetics, Vol.34, Iss.6, 1998-06, pp. : 497-502
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
It has been suggested that the minimum effective serum clozapine concentration for an acceptable clinical response (threshold value) is about 400 µg/L. This article argues against the use of therapeutic drug monitoring (TDM) as a tool to obtain clozapine concentrations of 400 µg/L in the individual patient from the start of clozapine treatment. The following arguments are presented:
It is concluded that the antipsychotic effects and adverse effects of clozapine occur over a very broad range of serum concentrations. In most countries the majority of patients are treated with clozapine concentrations well below the 400 µg/L suggested as threshold concentration for optimum response. Therefore, clinical judgement should always be primarily used for dose adjustments. TDM is useful to follow compliance and to adjust for extreme serum concentrations and revealing drug interactions.
400 µg/L;
Related content






By Dettling Michael Sachse Christoph Brockmöller Jürgen Schley Jürgen Müller-Oerlinghausen Bruno Pickersgill Ines Rolfs Arndt Schaub Rainer T. Schmider Jürgen
Psychopharmacology, Vol. 152, Iss. 1, 2000-09 ,pp. :


Therapeutic Drug Monitoring in the Treatment of Tuberculosis
Drugs, Vol. 62, Iss. 15, 2002-01 ,pp. :


Therapeutic Drug Monitoring for Antidepressant Drug Treatment
Current Pharmaceutical Design, Vol. 18, Iss. 36, 2012-12 ,pp. :